作者
Leonardo D’Aiuto, James McNulty, Caroll Hartline, Matthew Demers, Raj Kalkeri, Joel Wood, Lora McClain, Ansuman Chattopadhyay, Yun Zhi, Jennifer Naciri, Adam Smith, Robert Yolken, Kodavali Chowdari, Carlos Zepeda-Velazquez, Chanti Babu Dokuburra, Ernesto Marques, Roger Ptak, Paul Kinchington, Simon Watkins, Mark Prichard, David Bloom, Vishwajit Nimgaonkar
发表日期
2018/11/9
期刊
Scientific reports
卷号
8
期号
1
页码范围
16662
出版商
Nature Publishing Group UK
简介
Acyclovir (ACV) is an effective antiviral agent for treating lytic Herpes Simplex virus, type 1 (HSV-1) infections, and it has dramatically reduced the mortality rate of herpes simplex encephalitis. However, HSV-1 resistance to ACV and its derivatives is being increasingly documented, particularly among immunocompromised individuals. The burgeoning drug resistance compels the search for a new generation of more efficacious anti-herpetic drugs. We have previously shown that trans-dihydrolycoricidine (R430), a lycorane-type alkaloid derivative, effectively inhibits HSV-1 infections in cultured cells. We now report that R430 also inhibits ACV-resistant HSV-1 strains, accompanied by global inhibition of viral gene transcription and enrichment of H3K27me3 methylation on viral gene promoters. Furthermore, we demonstrate that R430 prevents HSV-1 reactivation from latency in an ex vivo rodent model. Finally, among a …
引用总数
2019202020212022202322324
学术搜索中的文章
L D'Aiuto, J McNulty, C Hartline, M Demers, R Kalkeri… - Scientific reports, 2018